{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:57:25Z","timestamp":1781333845204,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejso.2026.111859","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:07:43Z","timestamp":1777964863000},"page":"111859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating adherence to literature-derived systemic therapy standards for resectable intrahepatic cholangiocarcinoma: A systematic review and cohort study"],"prefix":"10.1016","volume":"52","author":[{"given":"Brady","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prejesh","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Scoggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-3387","authenticated-orcid":false,"given":"Robert C.G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejso.2026.111859_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2026.111859_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2026.111859_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.ejso.2026.111859_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejso.2026.111859_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111859_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2026.111859_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-017-2392-8","article-title":"The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis","volume":"143","author":"Schweitzer","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111859_bib8","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111859_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111859_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-Year overall survival update from the phase III TOPAZ-1 study","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.ejso.2026.111859_bib11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111859_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111859_bib13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"11","key":"10.1016\/j.ejso.2026.111859_bib14","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2026.111859_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines(R) insights: biliary tract cancers, version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.ejso.2026.111859_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.hpb.2024.04.003","article-title":"Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma","volume":"26","author":"Van Treeck","year":"2024","journal-title":"Hpb"},{"issue":"4","key":"10.1016\/j.ejso.2026.111859_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11605-023-05606-y","article-title":"Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study","volume":"27","author":"Parente","year":"2023","journal-title":"J Gastrointest Surg"},{"issue":"17","key":"10.1016\/j.ejso.2026.111859_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174320","article-title":"Systemic therapy is associated with improved oncologic outcomes in resectable stage II\/III intrahepatic cholangiocarcinoma: an examination of the national cancer database over the past decade","volume":"14","author":"Marcus","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejso.2026.111859_bib19","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","article-title":"Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease","volume":"28","author":"Utuama","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111859_bib20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","article-title":"Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma","volume":"221","author":"Sutton","year":"2021","journal-title":"Am J Surg"},{"issue":"11","key":"10.1016\/j.ejso.2026.111859_bib21","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","article-title":"Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience","volume":"28","author":"Mason","year":"2021","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:45:09Z","timestamp":1781333109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0748798326004786"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111859","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating adherence to literature-derived systemic therapy standards for resectable intrahepatic cholangiocarcinoma: A systematic review and cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111859"}}